Fox Chase Cancer Center | Strategic Alliance Partners

May 02, 2024

Fox Chase Cancer Center researchers showed that estrogen is metabolized in lungs, contributing to the development of lung cancer in never smokers.

April 18, 2024

Fox Chase Cancer Center is proud to welcome patients to its newly opened office, which is located at 502 Centennial Boulevard in Voorhees, New Jersey.

April 12, 2024

Fox Chase Cancer Center has been recognized by the QOPI Certification Program LLC as successfully completing a 3-year recertification for outpatient hematology-oncology practices that meet nationally recognized standards for quality cancer care.

April 10, 2024

The journal European Urology has named Fox Chase Cancer Center urologic oncologist Andres F. Correa, MD, its March 2024 Reviewer of the Month.

April 06, 2024

Sanjay S. Reddy, MD, FACS, of Fox Chase Cancer Center was recently chosen as a participant in the Society of Surgical Oncology’s inaugural Career Catalyst Mentorship Program.

April 03, 2024

Anthony Villano, MD, and Joceline Vu, MD, were recently elected members of the Education Committee of the Association for Academic Surgery.

April 01, 2024

Elizabeth Plimack, MD, MS, FASCO, recaps the discussion with key takeaways on recent updates in bladder cancer.

March 29, 2024

Efrat Dotan, MD, discusses a retrospective study aiming to understand the needs of geriatric patients with gastroesophageal cancer.

March 25, 2024

Experts on bladder cancer discuss exciting new agents and treatment strategies and where they can potentially fit into urothelial cancer treatment paradigms.

March 25, 2024

Focusing on metastatic urothelial carcinoma, the panel discusses the role of chemotherapy and outlines treatment sequencing approaches.

March 18, 2024

Evan Y. Yu, MD, provides insights on treatment approaches for patients with metastatic urothelial carcinoma in the second line and beyond.

March 18, 2024

The expert panel discusses how treatment strategies change based on cisplatin eligibility and the role of maintenance therapy in metastatic urothelial carcinoma.

March 12, 2024

Andrea Porpiglia, MD, MSc, FACS, and Sanjay Reddy, MD, FACS describe what makes the Complex General Surgical Oncology Fellowship at Fox Chase unique.

March 11, 2024

GU medical oncologists offer their impressions of recent updates in the metastatic urothelial carcinoma space, focusing on CheckMate 901 and EV-302.

March 11, 2024

Neeraj Agarwal, MD, FASCO, provides a comprehensive overview of recent data in metastatic urothelial carcinoma, highlighting the CheckMate 901 and EV-302 studies.

March 11, 2024

It is often said that one person can make a difference, but it is also evident that when we band together, we can achieve greatness.

March 04, 2024

Experts on muscle-invasive bladder cancer respond to recent data in adjuvant therapy that were presented at ASCO GU 2024.

March 04, 2024

Following an overview of the evolving adjuvant therapy space, Matthew Milowsky, MD, FASCO, reviews recent updates from ASCO GU 2024 in muscle-invasive bladder cancer.

February 26, 2024

Focusing on neoadjuvant therapy, the expert panel discusses ongoing clinical research in muscle-invasive bladder cancer and the potential role of novel strategies in the treatment space.

February 26, 2024

A panel of experts on bladder cancer introduce themselves and give an overview of the neoadjuvant therapy landscape for patients with muscle-invasive bladder cancer.